Fount Therapeutics

Fount Therapeutics, LLC is a sustainable drug discovery enterprise with a proven team of R & D talent that has created multiple launched medicines. Fount is maturing three newco subsidiaries: Kinnate Biopharma, Inc. (Oncology), Immanate Therapeutics, Inc. (Immunology & Immuno-Oncology), and Audere Medicines, Inc. (theme undisclosed).

Sapience Therapeutics is a development stage biotechnology company focused on developing its lead compound, an activating transcription Factor 5 inhibitor. Sapience licensed the technology from Columbia University and its initial program targets glioblastoma.

Asepticys is a development stage company focused on developing new generation chemically-unique medical disinfection/sterilization solutions effective against a broad spectrum of microbial pathogens that are clinically beneficial in a number of medical and consumer healthcare applications.

The Medicines Company (MDCO, NASDAQ) is developing (Phase III) a novel PCSK9 product for hyperlipidemia.

Carbon3D, a Silicon Valley based company, was founded in 2013 in Chapel Hill, NC. Working at the intersection of hardware, software and molecular science, Carbon3D is delivering on the promise of 3D printing, allowing commercial customers to go beyond basic prototyping to achieve 3D manufacturing.

A spinout from Duke University, developing immunotherapies for autoimmunity, cancer and immunodeficiency.

Innocrin Pharmaceutical Inc., a clinical stage company developing a lead small molecule which is both a CYP17 lyase-selective inhibitor and an androgen inhibitor to treat resistant hormonally-dependent breast and prostate cancers.

Developing "on demand" pharmaceuticals to restore voluntary control of bladder and bowel for people with spinal cord injury and neurological conditions.

Clinical-stage company developing small molecule therapies in the CDK4/6 & SERD categories to address significant unmet needs in oncology. GTHX, NASDAQ

An operating private equity fund that in-licenses drug candidates and develops through late-stage for ultimate sale to a commercializing company.

A clinical stage company developing opthalmic products in a novel delivery device.

An early stage company providing healthcare information to children/families using "super hero" comic formats.

A spinout from UNC, researching and developing novel cancer treatments, including MER Kinase inhibitors.

Provides professional, medically outfitted emergency airlift from Caribbean to US medical centers.